Evidence map›Paper›PMID 39478050›Full record

ArticleScientific reports2024

A nomogram incorporating linezolid and metabolite concentrations for predicting linezolid induced thrombocytopenia in patients with renal impairment.

Hanzhen Zhao, Lian Tang, Zhiwei Zhuang, Ying Zhang, Jingjing Li, Lufen Duan, Lu Shi, Chenqi Zhu, Jian Lu, Yunlong Yuan and 3 more

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Hanzhen Zhao *Department of Pharmacy, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, China.
Lian Tang *Department of Pharmacy, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, China.
Zhiwei Zhuang *Gusu School, Nanjing Medical University, Suzhou, China.
Ying ZhangDepartment of Pharmacy, The Suzhou Science and Technology Town Hospital, Suzhou, China.
Jingjing LiDepartment of Pharmacy, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, China.
Lufen DuanDepartment of Pharmacy, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, China.
Lu ShiDepartment of Pharmacy, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, China.
Chenqi ZhuDepartment of Pharmacy, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, China.
Jian LuIntensive Care Unit, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, China.
Yunlong YuanMedical laboratory, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, China.
Qian ZhangDepartment of Pharmacy, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, China. szsyyjk@163.com.
Yanxia YuDepartment of Pharmacy, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, China. yuyxsz@163.com.
Jinhui XuDepartment of Pharmacy, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, China. xujinhuinu@126.com.

Funding

Clinical Research Fund of Nanjing Medical University 2024KF0237Collaborative Innovation Project of Gusu School of Nanjing Medical University GSKY20240207Drug Safety Research Project by Adverse Drug Reactions Journal ADR2024MS21Gusu Talent Program GSWS2022069Jiangsu Pharmaceutical Association Hospital Pharmacy Research Project A202228Jiangsu Pharmaceutical Association Hospital Pharmacy Research Project H202109Jiangsu Research Hospital Association for Precision Medication JY202203Jiangsu Research Hospital Association for Precision Medication JY202204Jiangsu Research Hospital Association for Precision Medication JY202212Suzhou Pharmaceutical Association Hospital Pharmacy Research Project Syhky202312Suzhou Pharmaceutical Association Hospital Pharmacy Research Project Syhky202313Suzhou Science and Technology Project SKJYD2021170Suzhou Science and Technology Project SKJYD2021171Suzhou Science and Technology Project SKJYD2021172Suzhou Special Technical Project for Diagnosis and Treatment of Key Clinical Diseases LCZX202112Wellcome Trust 202427
6 · The paper itself

Abstract

A nomogram to estimate the risk of linezolid-induced thrombocytopenia in patients with renal impairment is not available. The aim of the study is to develop a nomogram for predicting linezolid-induced thrombocytopenia in patients with renal impairment and to investigate the incremental value of PNU-142300 concentration beyond clinical factors and linezolid trough concentration (C

Indexed as

LinezolidNomogramsRenal InsufficiencyThrombocytopeniaAdultAgedAged, 80 and overAnti-Bacterial AgentsFemaleHumansMaleMiddle AgedRetrospective StudiesRisk FactorsROC CurveAnti-Bacterial AgentsLinezolidLinezolidLinezolid-induced thrombocytopeniaNomogramPNU-142300Renal impairmentTrough concentration

Identifiers

PMID39478050
PMCPMC11525775

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.